Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
100%
Inhibitor Therapy
70%
EGFR Amplification
40%
Xenograft
30%
Tissue Specimens
20%
Molecular Characteristics
20%
Transplantable
20%
GBM Tumor
20%
Tumor
20%
Radiation Resistant
10%
EGFR Inhibition
10%
Signaling Pathway
10%
Phase I Trial
10%
Clinical Trials
10%
Mammalian Target of Rapamycin (mTOR)
10%
Treatment Group
10%
Cancer Treatment
10%
Molecular Pharmacology
10%
Tissue Archives
10%
North Central
10%
Drug-resistant Tumor
10%
Antitumor Effect
10%
Mayo Clinic
10%
Molecular Tumors
10%
Gene Alteration
10%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
10%
Customization
10%
Molecular Fingerprints
10%
Essential Pathway
10%
Tumor Characteristics
10%
Compensatory Signaling
10%
PTEN mutation
10%
Histopathologic
10%
Prediction Accuracy
10%
Malignant Behavior
10%
Direct Therapy
10%
ZD1839
10%
EGFR mutation
10%
2-phase
10%
Mutation Status
10%
Small Molecules
10%
Dual Inhibition
10%
Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
EGFR Inhibitors
100%
Tumor
40%
Neoplasm
30%
Xenograft
30%
Clinical Trial
20%
Cancer Therapy
10%
Signal Transduction
10%
Gene Mutation
10%
Finger Dermatoglyphics
10%
Gefitinib
10%
Treatment Group
10%
Mechanistic Target of Rapamycin
10%
Phosphotransferase Inhibitor
10%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Neoplasm
15%
Clinical Trial
10%